Intellectual Property
IP Management
ScinoPharm Taiwan is committed to enhancing our IP management framework through improving internal processes, strategic patent planning, and risk management. These efforts aim to protect our R&D achievements and support their commercialization.By aligning our IP priorities with the development of Active Pharmaceutical Ingredients (APIs) and formulations, we position intellectual property as a key driver for raising technological barriers and strengthening market competitiveness.
Our 2025 IP objectives focus on supporting R&D innovation, accelerating time-to-market, and ensuring freedom to operate (FTO). These priorities guide the way we manage, protect, and expand our IP assets across business functions.
The 2026 IP policy and strategic objectives of ScinoPharm Taiwan were presented to the Board of Directors for review and approval in November 2025.
2026 IP Policy
Cultivating an IP Management Culture to Foster R&D Innovations
As a global supplier of oncology-related generic APIs, ScinoPharm Taiwan offers deep technical expertise in developing and producing high-barrier APIs, with a focus on small molecules and peptides. We also provide process development and clinical trial material manufacturing services to international pharmaceutical partners. To strengthen our global presence and drive sustainable growth, we are integrating our formulation business to offer more comprehensive solutions and expand partnerships with global pharmaceutical companies.
Recognizing the importance of IP in sustaining innovation and business continuity, we have established the following 2026 IP policies to guide our operations:
- Position IP as a strategic business asset, with dedicated systems for its management and application to enhance innovation and competitiveness.
- Protect R&D outcomes through a combination of patents and trade secrets while actively developing and maintaining our IP portfolio.
- Conduct thorough IP risk assessments and develop design-around strategies to avoid infringement and maintain freedom to operate.
- Foster a company-wide IP culture that encourages innovation and raises awareness of intellectual property protection.
2026 IP Objectives
Establishing an Integrated IP Strategy to Strengthen Competitiveness
We are advancing our IP management by optimizing internal workflows, reinforcing our patent strategies, and addressing potential IP risks across product development stages. These actions are intended to safeguard our R&D innovations and support their path to market. By aligning our IP priorities with both API and formulation development, we aim to enhance technical differentiation and expand market opportunities.
Our 2026 IP objectives align with key goals: fostering innovation, reducing time-to-market, and ensuring freedom to operate. The specific goals for 2026 includes:
- Continue the implementation of the Taiwan Intellectual Property Management System (TIPS) and integrate it with existing internal IP management systems to optimize global patent portfolio strategies and maintenance management.
- In alignment with the Company’s development road-map, prioritize patent filings for 505(b)(2) new drugs and key process technologies.
- Enhance cross-functional collaboration between R&D and IP teams to systematically identify innovations appropriate for patent or trade secret protection, thereby reducing potential third-party IP infringement risks.
- Enhance patent infringement analysis and enforcement skills through internal knowledge-sharing meetings, and establish a patent invalidation (PIV) case database.
- Assess the impact of patent term extension systems on key products in major target markets and determine the earliest possible market entry dates.
- Establish a database covering patent systems and drug approval processes (for generics and hybrid drugs) in 8–10 countries or regions.
